scispace - formally typeset
A

Amy Joehlin-Price

Researcher at Cleveland Clinic

Publications -  35
Citations -  349

Amy Joehlin-Price is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 8, co-authored 26 publications receiving 215 citations. Previous affiliations of Amy Joehlin-Price include University of California, San Francisco & Ohio State University.

Papers
More filters
Journal ArticleDOI

The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas

Amy Joehlin-Price, +7 more
- 01 Jan 2017 - 
TL;DR: MELF is associated with LN metastases, even when compared with other infiltrative cases and shows multiple patterns of growth in positive LNs, and MELF cases additionally trended toward decreased time to extravaginal recurrence.
Journal ArticleDOI

Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma.

Umal Azmat, +4 more
- 11 Jan 2016 - 
TL;DR: A case of Graves' disease diagnosed after initiation of ipilimumab in a patient with melanoma and total thyroidectomy and left neck dissection is reported as a definitive treatment for both hyperthyroidism and residual melanoma.
Journal ArticleDOI

Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.

Zaibo Li, +8 more
- 01 Oct 2017 - 
TL;DR: PD-L1 is expressed in a significant proportion of EC and is associated with mismatch repair deficiency, potentially representing a mechanism of tumor immune evasion and a therapeutic target in EC.
Journal ArticleDOI

Mismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables

Amy Joehlin-Price, +6 more
- 01 Apr 2014 - 
TL;DR: A link between BMI and maintenance of the MMR system is not supported by the data because the only statistically significant association occurred in women <50years old with MSH2 and/or MSH6 abnormalities where Lynch syndrome related cases are expected to cluster.
Journal ArticleDOI

Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.

Amy Joehlin-Price, +5 more
- 01 Mar 2021 - 
TL;DR: This study corroborates the prognostic impact of molecular classification of high-grade endometrioid carcinoma of the uterus, achieved by readily available immunohistochemical stains in addition to POLE-mut analysis.